Publisher's Disclaimer. E-publishing ahead of print is increasingly important for the rapid dissemination of science. The Monaldi Archives for Chest Disease is, therefore, E-publishing PDF files of an early version of manuscripts that have undergone a regular peer review and have been accepted for publication, but have not been through the copyediting, typesetting, pagination and proofreading processes, which may lead to differences between this version and the final one. The final version of the manuscript will then appear on a regular issue of the journal. E-publishing of this PDF file has been approved by the authors.

Monaldi Arch Chest Dis 2021 [Online ahead of print]

To cite this Article:
Georgakopoulou VE, Garmpis N, Mermigkis D, et al. Pulmonary adverse events due to immune checkpoint inhibitors: A literature review. Monaldi Arch Chest Dis doi: 10.4081/monaldi.2021.2008
Pulmonary adverse events due to immune checkpoint inhibitors: A literature review

Vasiliki Epameinondas Georgakopoulou¹ MD; Nikolaos Garmpi²,³ MD, PhD; Dimitrios Mermigkis⁴ MD; Christos Damaskos ²,³ MD, Msc, PhD; Serafeim Chlapoutakis⁶ MD, Msc, PhD; Konstantinos Mantzouranis⁴ MD; Aikaterini Gkoufa⁵ MD; Chysovalantis Vasileios Papageorgiou¹ MD, PhD; Anna Garmpi⁷ MD; Sotiria Makrodimitri¹ MD; Evangelos Diamantis⁸ MD, PhD, Pagona Sklapani⁹ MD; Nikolaos Trakas¹⁰ PhD; Xanthi Tsiafaki⁴ MD, PhD

Affiliations:

¹ Pulmonology Department, Laiko General Hospital, Athens, Greece
² Second Department of Propedeutic Surgery, Laiko General Hospital, Medical School, National and Kapodistrian University of Athens, Athens, Greece
³ N.S. Christeas Laboratory of Experimental Surgery and Surgical Research, Medical School, National and Kapodistrian University of Athens, Athens, Greece
⁴ 1st Pulmonology Department Sismanogleio Hospital, Athens, Greece
⁵ First Department of Internal Medicine, Laiko General Hospital, Medical School, National and Kapodistrian University of Athens, Athens, Greece
⁶ Department of Thoracic Surgery, Agios Savvas Hospital, Athens, Greece
⁷ First Department of Propedeutic Internal Medicine, Laiko General Hospital, Medical School, National and Kapodistrian University of Athens, Athens, Greece
⁸ Unit of Endocrinology and Diabetes Center, Athens General Hospital “G. Gennimatas”, Athens, Greece
⁹ Department of Cytology, Mitera Hospital, Athens, Greece
¹⁰ Department of Biochemistry, Sismanogleio Hospital, Athens, Greece

Corresponding Author: Vasiliki Epameinondas Georgakopoulou, Pulmonology Department, Laiko General Hospital, 17 Agiou Thoma Street, 11527, Athens, Greece. E-mail: vaso_georgakopoulou@hotmail.com

Authors Contribution

Literature search: Evangelos Diamantis, Aikaterini Gkoufa, Anna Garmpi

Data collection: Dimitrios Mermigkis, Konstantinos Mantzouranis
Cancer immunotherapy aims to stimulate the immune system to fight against tumors, utilizing the presentation of molecules on the surface of the malignant cells that can be recognized by the antibodies of the immune system. Immune checkpoint inhibitors, a type of cancer immunotherapy, are broadly used in different types of cancer, improving patients’ survival and quality of life. However, treatment with these agents causes immune-related toxicities affecting many organs. The most frequent pulmonary adverse event is pneumonitis representing a non-infective inflammation localized to the interstitium and alveoli. Other lung toxicities include airway disease, pulmonary vasculitis, sarcoid-like reactions, infections, pleural effusions, pulmonary nodules, diaphragm myositis and allergic bronchopulmonary aspergillosis. This review aims to summarize these pulmonary adverse events, underlining the significance of an optimal expeditious diagnosis and management.

**Key words:** Immunotherapy; cancer; drug toxicity; immune checkpoint inhibitors.

**Introduction**
Cancer immunotherapy refers to the stimulation of the immune system to fight against tumors by improving on the immune system’s ability to fight malignancies. Cancer immunotherapy utilizes the fact that cancer cells often present on their surface cancer cells’ antigens, which are frequently proteins or various macromolecules and are detectable by the antibodies of the immune system. The altered immunotherapy antibodies are attached to the cancer cells’ antigens and therefore they mark and identify cancer cells to be inhibited or killed by the immune system [1,2].

Immunotherapies for cancer are divided into active and passive. Active forms of immunotherapy stimulate the immune system in order to destroy malignant cells. This attack is performed by targeting tumor antigens. Active cellular therapies remove cells of the immune system from the circulation or from the malignant lesion. Immune cells that can be utilized as active cellular therapies include
dendritic cells, natural killer cells, cytotoxic T-lymphocytes and lymphokine-activated killer cells [1,3].

Passive forms of immunotherapy promote current anti-cancer responses using monoclonal antibodies, cytokines and lymphocytes. Passive antibody therapies usually target the receptors on malignant cell’s surface. They include CD274, CD279 and CD20 antibodies. The modified antibodies are able to induce antibody-dependent cytotoxicity, to cause activation of the complement cascade, or can block a receptor from interrelating with its ligand, leading to cell apoptosis. Antibodies that have been approved are alemtuzumab, nivolumab, ofatumumab, ipilimumab, durvalumab, rituximab and pembrolizumab. Alemtuzumab is an anti-CD52 humanized IgG1 monoclonal antibody. Nivolumab is a human IgG4 antibody that acts through preventing T-cell inactivation by blocking the binding programmed death (ligand) 1 or 2 (PD-L1 or PD-L2). Ofatumumab is a human IgG1 antibody that binds to CD20. Ipilimumab is a human IgG1 antibody that targets the surface T lymphocyte-associated protein 4 (CTLA4) which binds to CD80 or CD86, preventing the binding of CD28 to these proteins, leading to negative regulation of T-cells activation. Durvalumab is an IgG1κ monoclonal antibody that acts by blocking the interaction of PD-L1 with the programmed death 1 (PD-1) and CD80 (B7.1) molecules. Rituximab is a chimeric monoclonal IgG1 antibody which targets CD20, being effective in treating specific B-cell malignancies. Pembrolizumab acts through blocking PD-1. The types and targets of these monoclonal antibodies are summarized in Table 1.

Immune checkpoints inhibitors (ICI), which are a form of passive immunotherapy including nivolumab, ipilimumab, durvalumab and pembrolizumab, is a revolutionizing treatment in a wide range of cancer types, as monotherapy or in combination with other agents, including chemotherapy [5]. In addition, these therapies are associated with improvement of health-related quality of life [6]. However, treatment with PD-1, PD-(L)1 and CTLA-4 inhibitors, is associated with a wide range of immune-related adverse events, caused by hyperactivation of the immune system, leading to, sometimes fatal, autoimmune reactions. These reactions may have an impact in every organ system [7].

The frequency of these adverse events depend on the agents used and on the specific features of patients. The incidence of fatal ICI related adverse events is estimated to be 0.3-1.3 %. Although adverse events from lungs are less common than toxicities to other organs, lung toxicity may be fatal and one of the most frequent causes of therapy withdrawal. Interstitial lung disease is the most frequent adverse event from lungs. Besides, pleural, vascular and airway involvement, sarcoid-like reactions and lung infections associated with ICI have been described mostly in case reports [8]. This review provides an overview of pulmonary adverse effects due to ICI. To our knowledge, is the first review to summarize all the types of lung toxicity, including the impact on small airways.
Search Strategy and Article Selection

The following search strategy was used. A systematic search of Pubmed/MEDLINE and Google Scholar was conducted in order to identify articles, reporting pulmonary adverse events due to ICIs. There were not language restrictions. The following terms were searched in combination: “Pulmonary Toxicity” OR “Lung Toxicity” OR “Pulmonary Adverse Events” OR “Lung Adverse Events” AND “Immune Checkpoint Inhibitors”.

The search was conducted by three reviewers (E.D, A.G and A.G). Articles were first screened for relevance by title. Then, they were evaluated by abstract. The relevant articles were enrolled for full-text review. Moreover, a manual search of the lists of the references of these texts was performed for identifying additional relevant articles.

Systematic search identified 1181 possibly relevant records, after exclusion of duplicates. Eight hundred and twenty-seven records were excluded after title, abstract or full text screening, since they were irrelevant. From the remaining 354 records, 278 records were excluded after careful screening of the titles and abstracts, since they did not mention pulmonary adverse events due to ICIs.

In the end, 76 articles, including case reports, case series and original articles, describing pulmonary adverse events due to ICIs, were enrolled.

Potential mechanisms for lung toxicity due to ICIs

The mechanism of pulmonary adverse events remains unclear, but it is thought to be associated with the immune dysregulation caused by ICIs. Three potential underlying mechanisms have been reported for the development of pulmonary adverse events due to ICIs [9]. First, the development of adverse events may be associated with increased T cell activity against cross-antigens expressed in malignant and normal cells. This hypothesis is supported by the finding in a study of increased lymphocytosis in bronchoalveolar lavage (BAL) obtained from patients with pneumonitis due to ICIs, mainly composed of CD4+ T cells. More specifically, the researchers found elevated central memory T cell (Tcm) counts and decreased CTLA-4 and PD-1 expressions in the Treg cells. PD-1+ and CTLA-4+ Tregs have negative regulatory impact on CD8+ T cells, conventional T cells, and pro-inflammatory responses of macrophages. Increasing activated alveolar T cell counts and attenuating the anti-inflammatory Treg phenotype may result in dysregulation of T cell activity. Second, increased levels of preexisting autoantibodies may also be an underlying mechanism.

Recent researches have demonstrated that preexisting anti-thyroglobulin antibodies, anti-rheumatoid factor antibodies, anti-thyroid peroxidase antibodies and antinuclear antibodies are probably associated with the development of adverse events in patients with lung cancer. However, the specific antibodies associated with pulmonary toxicity are still under exploration. Third, increased levels of inflammatory cytokines are also related to the occurrence of pulmonary adverse events. It has been
reported that in a patient with non-small cell lung cancer (NSCLC) who developed lung toxicity after atezolizumab administration, increased levels of C-reactive protein and interleukin-6 (IL-6) were observed. Cytokines can also be used as biomarkers for adverse events, and their increased expression correlates with severity of toxicity [10-14]. Figure 1 shows the potential mechanisms for lung toxicity due to ICIs.

**Interstitial Lung Disease**

Immune-related pneumonitis is a noninfectious inflammation confined to the interstitium and alveoli leading to a variety of computed tomography (CT) features and patterns of histopathology. These findings are stated as interstitial lung disease (ILD) [8]. Pneumonitis is graded from 1 to 4 based on the severity of the clinical symptoms [8]. Chest CT is the preferred imaging modality for the diagnosis of ILD. Opacifications with ground glass appearance, consolidations, and reticular opacities which predominate in sub-pleural and bibasilar regions are frequent radiology characteristics of numerous patterns of lung tissue injury [8]. However, imaging observations are insufficiently sensitive to differentiate drug-induced pneumonitis from other responsible factors for pneumonitis [8].

The risk factors for ICI-related ILD are unclear. It is suspected that factors such as sex, older age, tobacco use, history of lung disease, lung surgery or pulmonary radiotherapy may be related to development of ICI-related ILD. The incidence of ICI-related ILD may be influenced by type of tumor (especially NSCLC) and renal cell cancer) and type of ICI (higher incidence for PD-1 inhibitors compared to PD-L1 inhibitors) [14].

According to a meta-analysis, the overall ICI-related ILD incidence was estimated 2.7% for all grades and 0.8% for the most severe grades (grade ≥3). The incidence of ICI-related ILD is higher in combination therapy (including nivolumab and ipilimumab, given concurrently or sequentially, or nivolumab plus peptide vaccines) than in monotherapy. On the contrary, a combination of pembrolizumab with chemotherapeutic agents was not related to an increased risk of ICI-related ILD in patients with lung cancer. Moreover, the administration of durvalumab after chemoradiation in patients with locally advanced NSCLC was associated to an acceptable rate of pulmonary toxicity [15,16].

Clinical manifestations highly vary ranging from subclinical findings on chest CT to mild symptoms such as cough, mild dyspnea, low-grade fever and chest pain or to severe dyspnea, expeditiously progressive to respiratory insufficiency [8]. Moreover, there are no characteristic CT lesions or serological markers for ICI-related ILD [8]. The duration from ICI administration to development of ICI-related ILD varies from beginning of administration to withdrawal of the agent. According to a study, early-onset ICI-related ILD may have more severe course. ICI-related ILD is defined as the
occurrence of breathlessness and/or other respiratory symptoms, with new inflammatory manifestations on chest CT following treatment with ICI. The diagnosis is made after exclusion of pulmonary infection, progression of malignancy and other reasons [8]. Bronchoscopy with BAL is a significant diagnostic modality. Lymphocytosis with predominance of CD8-positive lymphocytosis and increased number of eosinophils are frequently noticed on BAL fluid [8]. Bronchial biopsies may provide supplementary data [8]. Evaluating the pulmonary function tests, abnormal findings in diffusing capacity might be early indication of lung injury preceding clinical symptoms and radiographic findings [8].

The injury patterns that are most commonly noted due to ICI toxicity in lungs are: nonspecific interstitial pneumonitis (NSIP), organizing pneumonia (OP) and diffuse alveolar damage (DAD) [7]. Organizing pneumonia is a type of ILD in which affecting sites are distal bronchioles, respiratory bronchioles, alveolar ducts and alveolar walls [17]. It is often associated with respiratory infections but clear mechanisms are unknown. Chest CT of patients with OP usually appears as ground-glass opacities or consolidations mainly observed in the lung periphery. Characteristic pathological finding is the abnormal proliferation of granulation tissue in distal airspaces [18]. In the literature there are several studies that describe organizing pneumonia as a type of lung toxicity due to cancer immunotherapy [19-37].

Nonspecific interstitial pneumonitis (NSIP) and diffuse alveolar damage (DAD) are additional patterns of lung toxicity associated with cancer immunotherapy [34-39, 41]. Nonspecific interstitial pneumonitis is a rare ILD. This type of ILD is frequently associated with human immunodeficiency virus (HIV) infection and autoimmune disorders such as dermatomyositis and scleroderma. Chest CT characteristic features of NSIP are ground-glass opacities, reticular infiltrates, and traction bronchiectasis while histologically, NSIP is characterized by uniform diffuse inflammatory cell infiltration, thickening of alveolar walls and dense fibrosis [40]. DAD is a severe type of pneumonitis originating from diffuse alveolar injury resulting in severe capillary leak and noncardiogenic pulmonary edema. Thoracic CT images of DAD reveal widespread airspace opacities while histological features of DAD are the formation of thickened alveolar membranes, deposition of hyaline membranes, and inflammatory cell infiltration [41].

Other reported histological and radiological patterns are “diffuse alveolar hemorrhage (DAH)” [8, 42-43], “hypersensitivity pneumonitis (HP)” [8, 34,36], “acute interstitial pneumonitis (AIP)” [8, 36-38], “acute respiratory distress syndrome (ARDS)” [8,39], “pulmonary fibrosis (PF)” [8, 48-49] and radiation recall pneumonitis [50-51].
**Treatment**

Corticosteroids are the basic treatment for ICI-related ILD, with 70%–80% of cases being controlled by regular corticosteroids administration. The overall duration of treatment with corticosteroids is approximately 6–8 weeks, usually less than 12 weeks. Empirical antibiotics, based on the principles of antimicrobial treatment, are also recommended during the initial treatment of ICI-related ILD. For patients with grade 2 pneumonitis or above, ICIs should be discontinued during treatment with corticosteroids [52].

Refractory ILD should raise thoughts about alternative diagnoses that should be excluded, such as infection and pulmonary embolism. There is no definite treatment for refractory ICI-related ILD. Agents that have been used according to existing literature include immunoglobulin, IL-6 receptor inhibitor and anti-tumor necrosis factor antibody. Additional immunosuppressive agents with slow effects, such as mycophenolate mofetil and cyclophosphamide, have also been recommended in some guidelines [52].

After recovery, rechallenge can be considered for selected individuals. The decision for rechallenge depends on response of the malignancy to ICI, grade of ICI-related ILD and response to corticosteroids and pulmonary function and the use of monotherapy or combination therapy. For patients who are rechallenged, close monitoring is required for ICI-related ILD. If patients present with relapse, permanent discontinuation of ICI administration is recommended [53].

**Other pulmonary disorders**

Additional pulmonary adverse events due to ICI have been described, including pleural, vascular and airway manifestations, sarcoid-like reactions, lung infections, diaphragma myositis and allergic bronchopulmonary aspergillosis. Tables 2,3,4 and 5 summarize all the cases describing additional pulmonary adverse events.

*Airway Disease*

Airway disease due to cancer immunotherapy is a rarely described pattern of lung toxicity. Bronchiolitis refers a nonspecific inflammation involving the small airways. Pembrolizumab-related obstructive bronchiolitis has been described in a 69-year-old woman with metastatic lung cancer. The diagnosis was made by lung function tests with severe obstructive pattern, without bronchodilator reversibility and mosaic attenuation on angiography [54]. Pembrolizumab-related obstructive bronchiolitis has also been described in a patient who presented with dry cough while receiving pembrolizumab for lung adenocarcinoma. The diagnosis of bronchiolitis was made by radiography and lung biopsy findings and his symptoms improved after the discontinuation of pembrolizumab and
with administration of erythromycin, an inhaled corticosteroid, a long-acting muscarinic antagonist, and a long-acting \( \beta_2 \) agonist [55].

Asthma is a chronic inflammatory disease of the airways of the lungs characterized by variable and recurring symptoms and reversible airflow obstruction with cough, wheezing, tightness, and dyspnea as the main symptoms [56]. Nivolumab-induced asthma without radiological or histological evidence of severe airway disease has been reported in a patient with non-small cell lung cancer [57]. In addition, in two cases, one with metastatic melanoma and one lung adenocarcinoma, both treated with nivolumab, patients developed isolated severe airway disease due to ICI. This report is the first to describe severe isolated airway disease associated with ICI with variable outcomes [58].

**Pulmonary Vasculitis**

The association of pulmonary vasculitis with immune checkpoint inhibitors has been described. Development of granulomatosis with polyangiitis (GPA) has been mentioned in a patient with metastatic melanoma who received ipilimumab and pembrolizumab [59]. In addition, development of Goodpasture's vasculitis has been mentioned in a patient suffering from advanced lung cancer treated with nivolumab [60].

**Sarcoid-like reactions**

Sarcoidosis is a systemic inflammatory disorder, resulting from an aberrant immune response to unknown factors and affecting multiple organ systems. Sarcoidosis inflammation is characterised by the development of non-creating granulomas in affected tissues. Lungs and intrathoracic lymph are involved most frequently. However every organ can be affected [61]. Sarcoid-like reaction describes granulomatous inflammation in the setting of active cancer or after the administration of effective therapy [62]. Several cases of sarcoidosis-like reactions due to cancer immunotherapy have been reported. Treatment with nivolumab has been associated with sarcoid-like granulomatosis in bronchi and mediastinal and hilar lymph nodes [61], [63-64]. Pembrolizumab administration has been described as the cause of sarcoid-like reactions such as bilateral hilar and mediastinal adenopathy and interstitial bilateral pulmonary lesions [63], [65-69]. The most frequent ICI associated with sarcoid-like reactions in respiratory system is ipilimumab. This inhibitor of cytotoxic T lymphocyte antigen (CTLA)-4 has been correlated with granulomatous lesion in lungs, pleura and intrathoracic lymph nodes [67], [69-77]. In addition, sarcoid-like reactions in lungs and intrathoracic lymph nodes can occur in the setting of combination of cancer immunotherapies [78, 79]. Besides, durvalumab has been described to cause granulomatous lung lesions in a case report [79].
It has been reported that a possible underlying mechanism for these responses may involve interleukin 17–producing cells, including CD4+ Th17 cells, that are thought to be expanded in sarcoidosis. A correlation between the presence of increased numbers of circulating Th17.1 cells in patients with melanoma before treatment with anti–PD-1 antibody therapy and the development of sarcoidosis has been mentioned, indicating that anti–PD-1 antibody therapy may enhance the actions of Th17.1 cells to lead to sarcoidosis. Th17.1 cells represent pathological inflammatory cells that produce several pro-inflammatory cytokines, such as interferon-γ, IL-17A, TNF-α and granulocyte-macrophage colony-stimulating factor (GM-CSF), which are related to rheumatoid inflammatory disorders [80].

**Lung Infections**

The treatment of refractory or severe adverse events due to cancer immunotherapy sometimes needs significant immunosuppression, including corticosteroids or tumor necrosis factor-alpha antagonists (anti-TNFα), increasing the risk for infections. In 2014, the first case of an opportunistic infection in a patient who received passive cancer immunotherapy, was described. The patient received ipilimumab for metastatic melanoma and developed adverse events for which he was treated with infliximab and corticosteroids. As a result of this immunosuppressive therapy he presented with Aspergillus fumigatus pneumonia [81]. A case of invasive pulmonary aspergillosis complicating treatment with pembrolizumab for metastatic lung carcinoma that got worse by multidrug-resistant Pseudomonas aeruginosa superinfection has also been described. The patient was treated concurrently with systemic steroids as anti-edema treatment for brain metastases [82].

Two lethal cases of patients who developed immune-related pneumonitis requiring immunosuppressive therapy during treatment with immune checkpoint inhibitors, consequently leading to *Pneumocystis jirovecii* pneumonia have also been presented [83]. In a retrospective study, by reviewing medical records of 740 patients with melanoma who received immune checkpoint inhibitors, 13 patients were found to have developed pneumonia, 2 patients have developed invasive aspergillosis and 3 patients have developed *Pneumocystis pneumonia* during their treatment [84]. The development of severe infections in cancer patients treated with immunotherapy, independently of immunosuppressive therapy, has rarely been mentioned in the literature. Inthasot et al. reported two cases of severe lung infections in patients receiving nivolumab for NSCLC who had not received any other immunosuppressive agents [85]. Moreover, the development of pleural aspergillosis in a patient who received durvalumab for non-small cell lung cancer has been reported [86]. Besides, the progression of chronic progressive pulmonary aspergillosis in a patient treated with nivolumab for lung adenocarcinoma, in the absence of obvious immunosuppression, has been described [87].
Additional toxicities of PD-1 and PD-(L)1 inhibitors include acute or reactivation of tuberculosis and infection from atypical mycobacteria. A recent retrospective review, that used the US Food and Drug Administration Adverse Events Reporting System (FAERS), revealed 14 cases of pulmonary active tuberculosis or reactivated tuberculosis and 5 cases of pulmonary infections from atypical mycobacteria in cancer patients treated with PD-1 and PD-(L)1 inhibitors [88]. It has been described that these responses may result from a hyperresponse of tuberculosis immunity, similar to immune reconstitution inflammatory syndrome (IRIS) [89]. Moreover, Jurado et al. in their study demonstrated the inhibitory function of the PD-1:PD-(L)s pathway during M. tuberculosis active infection, demonstrating that this pathway has a key role in the modulation of the immune response against mycobacteria [90].

**Pleural effusion**

Rapidly recurrent pleural effusion has been reported following cancer immunotherapy. Two cases of patients suffering from lung cancer receiving nivolumab, developed rapidly accumulating recurrent pleural effusions which required multiple thoracenteses [91]. According to one study, identical T cell clones in peritumoral pleural effusion and in bronchoalveolar lavage from areas with pneumonitis in a patient with cancer during therapy with immune-checkpoint inhibitors were found, suggesting that pleural effusion and pneumonitis might be induced by drug activated lymphocytes originating from tumor tissue [92].

**Pulmonary nodules**

Immune checkpoint inhibitors have been associated with the development of pulmonary nodules appearing misleadingly as metastases. Two patients who received pembrolizumab for metastatic melanoma presented pulmonary nodules. The histological examination of these nodules biopsy revealed inflammatory process without any malignant cell [93]. Pulmonary nodules occurring during the treatment with ICI may mimic malignant lesions and pose challenge in the differential diagnosis with cancer progression [94].

**Diaphragm myositis**

Two cases of diaphragm myositis have been mentioned with anti-PD-1 monotherapy and with a combination of anti-CTLA-4 and anti-PD-1 therapy. In the first case, anti-PD-1 treatment led to fatal
respiratory failure due to necrotising diaphragm myositis [95]. In the second case, the combination of agents led to fatal progressive hypoventilation [96].

Allergic Bronchopulmonary Aspergillosis

One case of recurrent allergic bronchopulmonary aspergillosis has been described [97]. The diagnosis was based on elevated serum immunoglobulin E and positive Aspergillus fumigatus IgE antibodies.

Conclusions

In conclusion, cancer immunotherapy, by disrupting the homeostasis of the immune system, can cause a wide range of pulmonary adverse events. An increasing number of patients treated with ICI have been reported to develop several lung toxicities and clinicians are gradually gaining more knowledge for these complications and for their appropriate management. Thus, clinicians should suspect this type of toxicity among patients receiving ICI, who present with pulmonary symptoms or abnormal findings on lung imaging.

Acknowledgements: None

Conflicts of interest: None

Funding: This research received no specific grant from any funding agency in the public, commercial, or not-for-profit sectors.

The Corresponding author confirms that all authors meet the criteria for authorship as outlined by the International Committee of Medical Journal Editors (ICMJE) criteria, have read the manuscript and agreed for publication.

References

1. Wikipedia [Internet]. Cancer immunotherapy. Availbale from: https://en.wikipedia.org/wiki/Cancer_immunotherapy
2. Farkona S, Diamandis EP, Blasutig IM. Cancer immunotherapy: The beginning of the end of cancer? BMC Med 2016;14:73.
3. Korneev KV, Atretkhany KN, Drutskaya MS, et al. TLR-signaling and proinflammatory cytokines as drivers of tumorigenesis. Cytokine 2017;89:127–35.
4. Kokate R. A systematic overview of cancer immunotherapy: an emerging therapy. Pharm Pharmacol Int J 2017;5:31–35.
5. Porcu M, De Silva P, Solinas C, et al. Immunotherapy associated pulmonary toxicity: biology behind clinical and radiological features. Cancers (Basel) 2019;11:305.
6. Brahmer JR, Rodriguez-Abreu D, Robinson AG, et al. Health-related quality-of-life results for pembrolizumab versus chemotherapy in advanced, PD-L1-positive NSCLC (KEYNOTE-
024): a multicentre, international, randomised, open-label phase 3 trial. Lancet Oncol 2017;18:1600-9.
7. Wang DY, Salem JE, Cohen JV, et al. Fatal toxic effects associated with immune checkpoint inhibitors: A systematic review and meta-analysis. JAMA Oncol 2018;4:1721-8.
8. Shannon VR, Anderson R, Blidner A, et al. Multinational Association of Supportive Care in Cancer (MASCC) 2020 clinical practice recommendations for the management of immune-related adverse events: pulmonary toxicity. Support Care Cancer 2020;28:6145-57.
9. Postow MA, Sidlow R, Hellmann MD. Immune-related adverse events associated with immune checkpoint blockade. N Engl J Med 2018;378:158-68.
10. Toi Y, Sugawara S, Sugisaka J, et al. Profiling preexisting antibodies in patients treated with anti-PD-1 therapy for advanced non-small cell lung cancer. JAMA Oncol 2019;5:376-83.
11. Naqash AR, Yang LV, Sanderlin EJ, et al. Interleukin-6 as one of the potential mediators of immune-related adverse events in non-small cell lung cancer patients treated with immune checkpoint blockade: evidence from a case report. Acta Oncol 2018;57:705-8.
12. Johnson DB, Balko JM, Biomarkers for immunotherapy toxicity: are cytokines the answer? Clin Cancer Res 2019; 25:1452-4.
13. Lim SY, Lee JH, Gide TN, et al. Circulating cytokines predict immune-related toxicity in melanoma patients receiving anti-PD-1-based immunotherapy. Clin Cancer Res 2019;25:557-63.
14. Zhai X, Zhang J, Tian Y, et al. The mechanism and risk factors for immune checkpoint inhibitor pneumonitis in non-small cell lung cancer patients. Cancer Biol Med 2020;17:599-611.
15. Nishino M, Giobbie-Hurder A, Hatabu H, et al. Incidence of programmed cell death 1 inhibitor-related pneumonitis in patients with advanced cancer: A systematic review and meta-analysis. JAMA Oncol 2016;2:1607-16.
16. Langer CJ, Gadgeel SM, Borghaei H, et al. Carboplatin and pemetrexed with or without pembrolizumab for advanced, non-squamous non-small-cell lung cancer: a randomised, phase 2 cohort of the open-label KEYNOTE-021 study. Lancet Oncol 2016;17:1497-508.
17. Epler GR. Bronchiolitis obliterans organizing pneumonia: definition and clinical features. Chest 1992;102:S2–6.
18. Zhong L, Altan M, Shannon VR, Sheshadri A. Immune-related adverse events: Pneumonitis. Adv Exp Med Biol 2020;1244:255-69.
19. Barjaktarevic IZ, Qadir N, Suri A, Santamauro JT, Stover D. Organizing pneumonia as a side effect of ipilimumab treatment of melanoma. Chest 2013;143:858-61.
20. Asher N, Marom EM, Ben-Betzalel G, et al. Recurrent pneumonitis in patients with melanoma treated with immune checkpoint inhibitors. Oncologist 2019;24:640-7.
21. Shibaki R, Akamatsu H, Fujimoto M, et al. Nivolumab induced radiation recall pneumonitis after two years of radiotherapy. Ann Oncol 2017;28:1404-5.
22. Nishino M, Chambers ES, Chong CR, et al. Anti-PD-1 inhibitor-related pneumonitis in non-small cell lung cancer. Cancer Immunol Res 2016;4:289-93.
23. Cho JY, Kim J, Lee JS, et al. Characteristics, incidence, and risk factors of immune checkpoint inhibitor-related pneumonitis in patients with non-small cell lung cancer. Lung Cancer 2018;125:150-6.
24. Nishino M, Ramaiya NH, Hatabu H, et al. PD-1 inhibitor-related pneumonitis in lymphoma patients treated with single-agent pembrolizumab therapy. Br J Haematol 2018;180:752-5.
25. Marvisi M, Ramponi S, Balzarini L, Mancini C. A "crazy paving" pattern on ct scan in a patient treated with pembrolizumab. Curr Drug Saf 2019;14:242-5.

26. Gouant V, Brosseau S, Naltet C, et al. Nivolumab-induced organizing pneumonitis in a patient with lung sarcomatoid carcinoma. Lung Cancer 2016;99:162-165.

27. Fiset PO, Shapera S, Butler MO, Tsao MS. Anti-PD-1-associated organizing pneumonia in a responding melanoma patient. Ann Oncol 2016;27:1649-50.

28. Rickard F, Hyams C, Low AT. Pneumonitis: a serious adverse effect of PD-L1 inhibitors including pembrolizumab. BMJ Case Rep 2018;2018:bcr2018224485.

29. Li H, Ma W, Yoneda KY, et al. Severe nivolumab-induced pneumonitis preceding durable clinical remission in a patient with refractory, metastatic lung squamous cell cancer: a case report. J Hematol Oncol 2017;10:64.

30. Koyama N, Iwase O, Nakashima E, et al. High incidence and early onset of nivolumab-induced pneumonitis: four case reports and literature review. BMC Pulm Med 2018;18:23.

31. Ip J, Beliao S, Valente-Matos R, Gil N. Pulmonary side effects of nivolumab in a patient treated for gynecological malignancy. Radiol Case Rep 2018;13:542-4.

32. Hsu PC, Li SH, Yang CT. Recurrent pneumonitis induced by atezolizumab (anti-programmed death ligand 1) in NSCLC patients who previously experienced anti-programmed death 1 immunotherapy-related pneumonitis. J Thorac Oncol 2018;13:e227-30.

33. Tonk EHJ, van Lindert ASR, Verhoeof JJC, Suijkerbuijk KPM. Acute-onset pneumonitis while administering the first dose of durvalumab. Case Rep Oncol 2019;12:621-4.

34. Naidoo J, Wang X, Woo KM, et al. Pneumonitis in patients treated with anti-programmed death-1/programmed death ligand 1 therapy. J Clin Oncol 2017;35:709-717.

35. Kichenadasse G, Miners JO, Mangoni AA, et al. Multiorgan immune-related adverse events during treatment with atezolizumab. J Natl Compr Canc Netw 2020;18:1191-9.

36. Delaunay M, Cadranel J, Lusque A, et al. Immune-checkpoint inhibitors associated with interstitial lung disease in cancer patients. Eur Respir J 2017;50:1700050.

37. Kato T, Masuda N, Nakanishi Y, et al. Nivolumab-induced interstitial lung disease analysis of two phase II studies patients with recurrent or advanced non-small-cell lung cancer. Lung Cancer 2017;104:111-8.

38. Bargagli E, Bonti V, Bindl A, et al. Fibrotic lung toxicity induced by cytotoxic drugs, radiation and immunotherapy in patients treated for lung cancer. Monaldi Arch Chest Dis 2018;88:917.

39. Reed VA, Rizvi N. Managing pulmonary toxicities associated with immunotherapy: A case discussion. Oncologist 2019;24:730-4.

40. Flaherty KR, Martinez FJ, Travis W, Lynch JP 3rd. Nonspecific interstitial pneumonia (NSIP) Semin Respir Crit Care Med 2001;22:423-34.

41. Kaarteenaho R, Kinnula VL. Diffuse alveolar damage: a common phenomenon in progressive interstitial lung disorders. Pulm Med 2011;2011:1.

42. Kanaoka K, Ikebe S, Ihara S, et al. Durvalumab-induced diffuse alveolar hemorrhage: an autopsy case report. Case Rep Oncol 2020;13:696-701.

43. Shannon VR, Subudhi SK, Huo L, Faiz SA. Diffuse alveolar hemorrhage with nivolumab monotherapy. Respir Med Case Rep 2020;30:101131.

44. Nakahama K, Tamiya A, Taniguchi Y, et al. Severe acute interstitial lung disease after nivolumab in three non-small cell lung cancer patients with imaging findings of airway obstruction adjacent to lung tumors. J Infect Chemother 2017;23:826-9.
45. Petri CR, Patell R, Batalini F, et al. Severe pulmonary toxicity from immune checkpoint inhibitor treated successfully with intravenous immunoglobulin: Case report and review of the literature. Respir Med Case Rep 2019;27:100834.

46. Helber HA, Hada AL, Pio RB, et al. Immunotherapy-induced pneumonitis: cases report. Einstein (Sao Paulo) 2018;16:eRC4030.

47. Park H, Hatabu H, Ricciuti B, et al. Immune-related adverse events on body CT in patients with small-cell lung cancer treated with immune-checkpoint inhibitors. Eur J Radiol 2020;132:109275.

48. Yamakawa H, Oba T, Ohta H, et al. Nintedanib allows retreatment with atezolizumab of combined non-small cell lung cancer/idiopathic pulmonary fibrosis after atezolizumab-induced pneumonitis: a case report. BMC Pulm Med 2019;19:156.

49. Nguyen M, Islam MR, Lim SW, et al. Pembrolizumab induced ocular hypotony with near complete vision loss, interstitial pulmonary fibrosis and arthritis. Front Oncol 2019;9:944.

50. Kalisz KR, Ramaiya NH, Laukamp KR, Gupta A. Immune checkpoint inhibitor therapy-related pneumonitis: patterns and management. Radiographics 2019;39:1923-37.

51. Schoenfeld JD, Nishino M, Severgnini M, et al. Pneumonitis resulting from radiation and immune checkpoint blockade illustrates characteristic clinical, radiologic and circulating biomarker features. J Immunother Cancer 2019;7:112.

52. Wang H, Guo X, Zhou J, et al. Clinical diagnosis and treatment of immune checkpoint inhibitor-associated pneumonitis. Thorac Cancer 2020;11:191-7.

53. Spain L, Walls G, Messiou C, et al. Efficacy and toxicity of rechallenge with combination immune checkpoint blockade in metastatic melanoma: A case series. Cancer Immunol Immunother 2017;66:113–7.

54. Blanchard A, Bouchard N. Pembrolizumab-induced obstructive bronchiolitis in a patient with stage IV non-small-cell lung cancer. Curr Oncol 2019;26:e571-3.

55. Yamaya T, Hee HM, Aoyagi T, et al. Pembrolizumab associated bronchiolitis in an elderly lung cancer patient required the treatment with an inhaled corticosteroid, erythromycin and bronchodilators. Respir Med Case Rep 2019;28:100866.

56. Lemanske RF, Busse WW. Asthma: clinical expression and molecular mechanisms. J Allergy Clin Immunol 2010;125:S95-102.

57. Maeno K, Fukuda S, Oguri T, Niimi A. Nivolumab-induced asthma in a patient with non-small-cell lung cancer. Ann Oncol 2017;28:2891.

58. Mitropoulou G, Daccord C, Sauty A, et al. Immunotherapy-induced airway disease: a new pattern of lung toxicity of immune checkpoint inhibitors. Respiration 2020;99:181-6.

59. van den Brom RR, Abdulahad WH, Rutgers A, et al. Rapid granulomatosis with polyangiitis induced by immune checkpoint inhibition. Rheumatology (Oxford) 2016;55:1143-5.

60. Takahashi N, Tsuji K, Tamiya H, et al. Goodpasture's disease in a patient with advanced lung cancer treated with nivolumab: An autopsy case report. Lung Cancer. 2018;122:22-4.

61. Montaudie H, Pradelli J, Passeron T, et al. Pulmonary sarcoid like granulomatosis induced by nivolumab. Br J Dermatol 2017;176:1060-3.

62. Hunt BM, Vallieres E, Buduhan G, et al. Sarcoidosis as a benign cause of lymphadenopathy in cancer patients. Am J Surg 2009;197:629e632.

63. Frohlich M, Wang H, Sakr L. Sarcoid-like reaction discovered on EBUS-TBNA of intrathoracic lymph nodes during immunotherapy for metastatic melanoma. J Immunother 2020;43:75-8.
64. Danlos FX, Pages C, Baroudjian B, et al. Nivolumab-induced Sarcoïd-like Granulomatous reaction in a patient with advanced melanoma. Chest 2016;149:e133-6.
65. Cousin S, Toulmonde M, Kind M, et al. Pulmonary sarcoidosis induced by the anti-PD1 monoclonal antibody pembrolizumab. Ann Oncol 2016;27:1178-9.
66. Al-Dliw M, Megri M, Shahoub I, et al. Pembrolizumab reactivates pulmonary granulomatosis. Respir Med Case Rep 2017;22:126-9.
67. Tetzlaff MT, Nelson KC, Diab A, et al. Granulomatous/sarcoïd-like lesions associated with checkpoint inhibitors: a marker of therapy response in a subset of melanoma patients. J Immunother Cancer 2018;6:14.
68. Cotliar J, Querfeld C, Boswell WJ, et al. Pembrolizumab associated sarcoidosis. JAAD Case Rep 2016;2:290–9.
69. Firwana B, Ravilla R, Raval M, et al. Sarcoïdosis-like syndrome and lymphadenopathy due to checkpoint inhibitors. J Oncol Pharm Pract 2017;23:620–24.
70. Eckert A, Schoeffler A, Dalle S, et al. Anti-CTLA4 monoclonal antibody induced sarcoidosis in a metastatic melanoma patient. Dermatology 2009;218:69–70.
71. Vogel WV, Guislain A, Kvistborg P, et al. Ipilimumab-induced sarcoidosis in a patient with metastatic melanoma undergoing complete remission. J Clin Oncol 2012;30:e7–10.
72. Wilgenhof S, Morlion V, Seghers AC, et al. Sarcoïdosis in a patient with metastatic melanoma sequentially treated with anti-CTLA-4 monoclonal antibody and selective BRAF inhibitor. Anticancer Res 2012;32:1355-9.
73. Berthod G, Lazor R, Letovanec I, et al. Pulmonary sarcoid-like granulomatosis induced by ipilimumab. J Clin Oncol 2012;30:e156–9.
74. Tissot C, Carsin A, Freymond N, et al. Sarcoïdosis complicating anti-cytotoxic T-lymphocyte-associated antigen-4 monoclonal antibody biotherapy. Eur Respir J 2013;41:246–7.
75. Reule RB, North JP. Cutaneous and pulmonary sarcoidosis-like reaction associated with ipilimumab. J Am Acad Dermatol 2013;69:e272–3.
76. Toumeh A, Sakhi R, Shah S, et al. Ipilimumab-induced Granulomatous disease occurring simultaneously with disease progression in a patient with metastatic melanoma. Am J Ther 2016;23:e1068–71.
77. van den Eertwegh AJ, Versluis J, van den Berg HP, et al. Combined immunotherapy with granulocyte-macrophage colony-stimulating factor-transduced allogeneic prostate cancer cells and ipilimumab in patients with metastatic castration-resistant prostate cancer: a phase 1 dose-escalation trial. Lancet Oncol 2012;13:509–17.
78. Reuss JE, Kunk PR, Stowman AM, et al. Sarcoïdosis in the setting of combination ipilimumab and nivolumab immunotherapy: a case report & review of the literature. J Immunother Cancer 2016;4:94.
79. Faviez G, Bousquet E, Rabeau A, et al. Sarcoïd-like granulomatosis in cancer patients treated with immune checkpoints inhibitors. Rev Mal Respir 2018;35:963-7.
80. Gkiozos I, Kopitopoulou A, Kalkanis A, et al. Sarcoïdosis-like reactions induced by checkpoint inhibitors. J Thorac Oncol 2018;13:1076-82.
81. Kyi C, Hellmann MD, Wolchok JD, et al. Opportunistic infections in patients treated with immunotherapy for cancer. J Immunother Cancer 2014;2:19.
82. Oltolini C, Ripa M, Andolina A, et al. Invasive pulmonary aspergillosis complicated by carbapenem-resistant Pseudomonas aeruginosa infection during pembrolizumab immunotherapy for metastatic lung adenocarcinoma: Case report and review of the literature. Mycopathologia 2019;184:181-5.
83. Schwarz M, Kocher F, Niedersuess-Beke D, et al. Immunosuppression for immune checkpoint-related toxicity can cause pneumocystis jirovecii pneumonia (PJP) in non-small-cell lung cancer (NSCLC): A report of 2 cases. Clin Lung Cancer 2019;20:e247-e50.
84. Del Castillo M, Romero FA, Argüello E, et al. The spectrum of serious infections among patients receiving immune checkpoint blockade for the treatment of melanoma. Clin Infect Dis 2016;63:1490-3.
85. Inthasot V, Bruyneel M, Muylle I, Ninane V. Severe pulmonary infections complicating nivolumab treatment for lung cancer: a report of two cases. Acta Clin Belg 2020;75:308-10.
86. Gupta A, Tun A, Ticona K, Baqui A, Guevara E. Invasive aspergillosis in a patient with stage III (or 3a or 3b) non-small-cell lung cancer treated with durvalumab. Case Rep Oncol Med 2019;2019:2178925.
87. Uchida N, Fujita K, Nakatani K, Mio T. Acute progression of aspergillosis in a patient with lung cancer receiving nivolumab. Respirol Case Rep 2017;6:e00289.
88. Anand K, Sahu G, Burns E, et al. Mycobacterial infections due to PD-1 and PD-L1 checkpoint inhibitors. ESMO Open 2020;5:e000866.
89. Fujita K, Terashima T, Mio T. Anti-PD1 antibody treatment and the development of acute pulmonary tuberculosis. J Thorac Oncol 2016;11:2238-40.
90. Jurado JO, Alvarez IB, Pasquinelli V, et al. Programmed death (PD)-1:PD-ligand 1/PD-ligand 2 pathway inhibits T cell effector functions during human tuberculosis. J Immunol 2008;181:116-25.
91. Kolla BC, Patel MR. Recurrent pleural effusions and cardiac tamponade as possible manifestations of pseudoprogression associated with nivolumab therapy- a report of two cases. J Immunother Cancer 2016;4:80.
92. Tanaka K, Yanagihara T, Ikematsu Y, et al. Detection of identical T cell clones in peritumoral pleural effusion and pneumonitis lesions in a cancer patient during immune-checkpoint blockade. Oncotarget 2018;9:30587-93.
93. Pradere P, Boutros C, Scoazec JY, et al. Pulmonary nodules and immunotherapy: disease progression or toxicity of anti-PD1/anti-PDL1 checkpoint inhibitors? Eur J Cancer 2018;93:144-6.
94. Safa H, Bhosale P, Weissferdt A, Oliva ICG. Difficulties in differentiating between checkpoint inhibitor pneumonitis and lung metastasis in a patient with melanoma. Immunotherapy 2020;12:293-8.
95. Haddox CL, Shenoy N, Shah KK, et al. Pembrolizumab induced bulbar myopathy and respiratory failure with necrotizing myositis of the diaphragm. Ann Oncol 2017;28:673-5.
96. John S, Antonia SJ, Rose TA, et al. Progressive hypoventilation due to mixed CD8(+) and CD4(+) lymphocytic polymyositis following tremelimumab–durvalumab treatment. J Immunother Cancer 2017;5:54.
97. Pradere P, Michot JM, Champiat S, et al. Allergic broncho-pulmonary aspergillosis following treatment with an anti-programmed cell death protein 1 monoclonal antibody therapy. Eur J Cancer 2017;75:308-9.
Table 1. Targets of monoclonal antibodies alemtuzumab, nivolumab, ofatumumab, ipilimumab, durvalumab, rituximab and pembrolizumab.

| Antibody      | Type         | Target       |
|---------------|--------------|--------------|
| Alemtuzumab   | Humanized    | CD52         |
| Nivolumab     | Human        | PD-1         |
| Ofatumumab    | Human        | CD20         |
| Ipilimumab    | Human        | CTLA-4       |
| Durvalumab    | Human        | PD-L1        |
| Rituximab     | Chimeric     | CD20         |
| Pembrolizumab | Humanized    | PD-1         |

*CTLA-4: T Lymphocyte-Associated Protein 4; PD-1: Programmed Death-1; PD-L1: Programmed Death Ligand-1
Table 2. Cases describing airway and vascular disease due to ICIs.

| #  | Case                   | Age/gender | ICI           | Type of toxicity                  | Type of cancer | Management                                                                 |
|----|------------------------|------------|---------------|-----------------------------------|----------------|-----------------------------------------------------------------------------|
| 1  | Blanchard et al. [54]  | 69/F       | Pembrolizumab | Obstructive bronchiolitis         | NSCLC          | Discontinuation of the drug Corticosteroids Inhaled bronchodilators Azithromycin |
| 2  | Yamaya et al. [55]     | 76/M       | Pembrolizumab | Obstructive bronchiolitis         | Lung adenocarcinoma | Discontinuation of the drug Erythromycin Inhaled bronchodilators and corticosteroids |
| 3  | Maeno et al. [57]      | 50/M       | Nivolumab     | Asthma                            | Lung adenocarcinoma | Corticosteroids Inhaled bronchodilators and corticosteroids                   |
| 4  | Mitropoulou et al. [58]| 65/F       | Nivolumab     | Isolated severe airway disease    | Melanoma        | Discontinuation of the drug Corticosteroids Inhaled bronchodilators and corticosteroids Azithromycin |
| 5  | Mitropoulou et al. [58]| 58/M       | Nivolumab     | Isolated severe airway disease    | Lung adenocarcinoma | Discontinuation of the drug Corticosteroids                                  |
| 6  | van den Brom et al. [59]| 56/F     | Ipilimumab/Pembrolizumab | Granulomatosis with polyangiitis | Melanoma        | Corticosteroids                                                              |
| 7  | Takahashi et al. [60]  | 74/M       | Nivolumab     | Goodpasture’s disease             | Lung adenocarcinoma | Discontinuation of the drug Corticosteroids Plasma exchange                   |

*F: Female; ICI: Immune Checkpoint Inhibitors; M: Male; NSCLC: Non Small Cell Lung Carcinoma
| #  | Case                        | Age/gender | ICI        | Location                                                   | Type of cancer | Management            |
|----|-----------------------------|------------|------------|------------------------------------------------------------|----------------|-----------------------|
| 1  | Montaudie et al. [61]       | 56/M       | Nivolumab  | Lung Eyes Parotid glands                                   | Melanoma       | Corticosteroids       |
| 2  | Frohlich et al. [63]        | 57/M       | Nivolumab  | Mediastinal lymph nodes                                    | Melanoma       | Discontinuation of the drug |
| 3  | Frohlich et al. [63]        | 53/M       | Pembrolizumab | Mediastinal lymph nodes                                    | Melanoma       | Discontinuation of the drug |
| 4  | Danlos et al. [64]          | 57/M       | Nivolumab  | Mediastinal lymph nodes Skin                               | Melanoma       | Discontinuation of the drug |
| 5  | Cousin et al [65]           | 55/F       | Pembrolizumab | Mediastinal lymph nodes Lung Uterine leiomyosarcoma       | Melanoma       | Discontinuation of the drug |
| 6  | Al-Dliw et al. [66]         | 65/F       | Pembrolizumab | Mediastinal lymph nodes Lung                               | Melanoma       | Discontinuation of the drug Corticosteroids |
| 7  | Tetzlaff et al. [67]        | 76/M       | Pembrolizumab | Gastric, Retroperitoneal, Paratracheal lymph nodes, Erythema and swelling of the forearms | Melanoma       | Discontinuation of the drug |
| 8  | Tetzlaff et al. [67]        | 44/F       | Ipilimumab | Mediastinal and hilar lymph nodes Skin                    | Melanoma       | Discontinuation of the drug |
| 9  | Tetzlaff et al. [67]        | 68/M       | Pembrolizumab | Mediastinal and hilar lymph nodes Bones Eyes            | Melanoma       | No specific intervention |
| 10 | Firwana et al. [69]         | 41/M       | Ipilimumab | Retroauricular, occipital, cervical, axillary, hilar, mediastinal, iliac, inguinal lymph nodes Spleen | Melanoma       | Discontinuation of the drug |
| 11 | Firwana et al. [69]         | 57/F       | Ipilimumab | Skin            | Melanoma       | N/A                   |
|   | Authors            | Gender/ Age | Therapy                  | Findings                                                                 | Diagnosis   | Treatment/ Comment                                      |
|---|--------------------|-------------|--------------------------|---------------------------------------------------------------------------|-------------|---------------------------------------------------------|
| 12| Firwana et al. [69] | 37/F        | Pembrolizumab            | Cervical, axillary, mediastinal, and retroperitoneal lymph nodes Lung Skin | Melanoma    | Discontinuation of the drug                            |
| 13| Eckert et al. [70]  | 67/F        | Ipilimumab               | Mediastinal lymph nodes Lungs                                             | Melanoma    | Discontinuation of the drug                            |
| 14| Vogel et al. [71]   | 49/M        | Ipilimumab               | Mediastinal and hilar lymph nodes                                         | Melanoma    | No specific intervention                               |
| 15| Wilgenhof et al. [72]| 48/F        | Ipilimumab               | Neck, axillae, mediastinal and retroperitoneal lymph nodes Lungs Spleen   | Melanoma    | Corticosteroids                                        |
| 16| Berthod et al. [73] | 63/M        | Ipilimumab               | Lung                                                                      | Melanoma    | Corticosteroids                                        |
| 17| Tissot et al. [74]  | 57/M        | Ipilimumab               | Bilateral hilar lymph nodes Lung Skin                                     | Melanoma    | Discontinuation of the drug                            |
| 18| Reule et al. [75]   | 55/M        | Ipilimumab               | Hilar and mediastinal lymph nodes Lungs Skin                               | Melanoma    | Corticosteroids                                        |
| 19| Toumeh et al. [76]  | 26/F        | Ipilimumab               | Mediastinal lymph nodes Lungs Skin                                         | Melanoma    | Corticosteroids                                        |
| 20| Reuss et al. [78]   | 32/F        | Ipilimumab/Nivolumab     | Supraclavicular, mediastinal, right hilar and left iliac lymph nodes Skin | Melanoma    | Discontinuation of ipilimumab                          |
| 21| Faviez et al. [79]  | 61/N/A      | Ipilimumab/Nivolumab     | Subdiaphragmatic lymph nodes Lungs Spleen                                 | SCLC        | Discontinuation of treatment                           |
| 22| Faviez et al. [79]  | 47/N/A      | Ipilimumab/Nivolumab     | Mediastinal lymph nodes Lungs                                              | Melanoma    | Discontinuation of therapy Corticosteroids            |
Table 4. Cases describing lung infections due to ICIs.

| #  | Case                  | Age/gender | ICI      | Pathogen          | Type of cancer | Management                                                                 |
|----|-----------------------|------------|----------|-------------------|----------------|-----------------------------------------------------------------------------|
| 1  | Kyi et al. [81]       | 48/M       | Ipilimumab | *Aspergillus fumigatus* | Melanoma       | Voriconazole and liposomal amphotericin B                                  |
| 2  | Oltolini et al. [82]  | 62/F       | Pembrolizumab | *Aspergillus spp* *P. aeruginosa* | Lung Adenocarcinoma | Voriconazole, Ceftolozane/tazobactam Ciprofloxacin                        |
| 3  | Schwarz et al. [83]   | 79/M       | Nivolumab  | *Pneumocystis Jirovecii* | NSCLC          | Trimethoprim-Sulfamethoxazole                                               |
| 4  | Schwarz et al. [83]   | 52/M       | Nivolumab  | *Pneumocystis Jirovecii* | NSCLC          | Trimethoprim-Sulfamethoxazole                                               |
| 5  | Inthasot et al. [85]  | 69/M       | Nivolumab  | *Mycobacterium tuberculosis* | Lung Adenocarcinoma | Antituberculosis treatment                                                 |
| 6  | Inthasot et al. [85]  | 57/F       | Nivolumab  | *Aspergillus fumigatus* | Squamous cell lung carcinoma | Voriconazole                                                               |
| 7  | Gupta et al. [86]     | 63/M       | Durvalumab  | *Aspergillus fumigatus* | NSCLC          | Voriconazole                                                               |
| 8  | Uchida et al. [87]    | 65/M       | Nivolumab  | *Aspergillus fumigatus* | Lung Adenocarcinoma | Voriconazole                                                               |
| 9  | Fujita et al. [89]    | 72/M       | Nivolumab  | *Mycobacterium tuberculosis* | Squamous cell lung carcinoma | Antituberculosis treatment                                                 |

*F: Female; ICI: Immune Checkpoint Inhibitors; M: Male; N/A: Not Available; SCLC: Small Cell Lung Cancer*
Table 5. Cases describing pleural disease, pulmonary nodules, diaphragm myositis and ABPA due to ICIs.

| # | Case                              | Age/ gender | ICI          | Type of toxicity       | Type of cancer          | Management                                                                 |
|---|----------------------------------|-------------|--------------|------------------------|-------------------------|-----------------------------------------------------------------------------|
| 1 | Kolla et al. [91]                | 46/M        | Nivolumab    | Pleural Effusion        | SCLC                    | Multiple thoracocenteses                                                    |
| 2 | Kolla et al. [91]                | 54/F        | Nivolumab    | Pleural Effusion        | Lung Adenocarcinoma      | Multiple thoracocenteses Corticosteroids                                    |
| 3 | Pradère et al. [93]              | 40/M        | Pembrolizumab| Pulmonary Nodules       | Melanoma                | Discontinuation of the drug                                                |
| 4 | Pradère et al. [93]              | 44/M        | Pembrolizumab| Pulmonary Nodules       | Melanoma                | Discontinuation of the drug                                                |
| 5 | Safa et al. [94]                 | 46/M        | Nivolumab    | Pulmonary Nodules       | Melanoma                | Discontinuation of the drug                                                |
| 6 | Haddox et al. [95]               | 78/M        | Pembrolizumab| Necrotizing myositis of the diaphragm | Melanoma                | Discontinuation of the drug                                                |
| 7 | John et al. [96]                 | 64/F        | Tremelimumab/Durvvalumab. | Myositis of the diaphragm | Lung Adenocarcinoma        | Discontinuation of the drug Corticosteroids Continuous bilevel positive airway pressure Intravenous polyvalent Plasma exchange Pyridostigmine |
| 8 | Pradere et al. [97]              | 58/M        | Anti-program death 1 (PD-1) monoclonal antibody | ABPA                   | Renal cell carcinoma         | Itraconazole Corticosteroids                                                |

*ABPA: Allergic Bronchopulmonary Aspergillosis; F: Female; M: Male; SCLC: Small Cell Lung Carcinoma*
Three potential underlying mechanisms have been reported for the development of pulmonary adverse events due to ICIs. First, the development of adverse events may be associated with increased T cell activity against cross-antigens expressed in malignant and normal lung cells as it is indicated by observation of increased lymphocytosis in bronchoalveolar lavage (BAL) obtained from patients with pneumonitis due to ICIs, mainly composed of CD4+ T cells. Second, increased levels of preexisting autoantibodies, such as anti-thyroglobulin antibodies, anti-rheumatoid factor antibodies, anti-thyroid peroxidase antibodies and antinuclear antibodies may be also representing an underlying mechanism. Third, increased levels of inflammatory cytokines, such as C-reactive protein and interleukin-6 (IL-6), are also related to the occurrence of pulmonary adverse events.